[Federal Register Volume 59, Number 147 (Tuesday, August 2, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-18777]


[[Page Unknown]]

[Federal Register: August 2, 1994]


-----------------------------------------------------------------------


DEPARTMENT OF HEALTH AND HUMAN SERVICES
 

Findings of Scientific Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the Office of Research Integrity 
(ORI) has made final findings of scientific misconduct in the following 
case:
    Anand Tewari, M.D., Stanford University. The Division of Research 
Investigations (DRI) of the Office of Research Integrity (ORI) 
conducted an investigation into possible scientific misconduct on the 
part of Dr. Tewari while a postdoctoral fellow in the Department of 
Surgery, Stanford University School of Medicine. ORI concluded that Dr. 
Tewari committed scientific misconduct in clinical research supported 
by an NIH grant by fabricating ophthalmologic examination results; 
fabricating and falsifying blood gas data; fabricating and falsifying 
values for glycerol determinations; falsifying standard errors and 
including fabricated data on platelet counts in a published article, 
``Effects of interleukin-1 on platlet counts'' (The Lancet 336:712-714 
(1990)), and related abstracts; and providing to his supervisors 
summaries of data that included falsified and fabricated data which 
were used in a PHS grant application. The published article containing 
the falsified and fabricated data was retracted on August 22, 1992. The 
Lancet 340:496. Dr. Tewari accepted the ORI findings and agreed to a 
Voluntary Exclusion and Settlement Agreement under which he may not 
apply for Federal grant or contract funds except for the non-research 
training or practice of clinical medicine, and may not serve on PHS 
advisory committees, boards, or peer review groups for a five-year 
period beginning March 1, 1994.

FOR FURTHER INFORMATION CONTACT: Director, Division of Research 
Investigations Office of Research Integrity 301-443-5330.

    Dated: July 27, 1994.
Lyle W. Bivins,
Director, Office of Research Integrity.
[FR Doc. 94-18777 Filed 8-1-94; 8:45 am]
BILLING CODE 4160-17-M